Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL.
- Author:
Jong Eun YEON
1
Author Information
- Publication Type:Review
- Keywords: Hepatitis C virus; Direct acting antiviral; Resistance associated substitutions; Genotype; Liver cirrhosis
- MeSH: Antiviral Agents; Compliance; Genotype; Hepacivirus; Hepatitis C, Chronic*; Hepatitis, Chronic*; Humans; Korea; Liver Cirrhosis; Liver*
- From:Clinical and Molecular Hepatology 2018;24(3):278-293
- CountryRepublic of Korea
- Language:English
- Abstract: The paradigm for the treatment of chronic hepatitis C (CHC) has been changed due to the development of direct acting antivirals (DAAs) of hepatitis C virus (HCV). The high sustained virologic response rate and ease of administration makes the DAAs approach ideal to contribute to the complete eradication of HCV. Currently, treatment options for individual patients vary depending on the genotype or subtype of HCV, presence or absence of liver cirrhosis, previous experience of antiviral treatment or resistance associated substitutions. Because of drug avalilability, cost-effectiveness, preference, compliance and greater possibility of desirable effects and presumed patient-important outcomes may vary between countries, treatment options for individual patients are different. The review focuses on the comparing the current treatment options for CHC in other continents with the 2017 Korea Association for the Study of the Liver guidelines.
